$51.63
2.034.09%
Last update: Nov 9, 4:29 PM
Travere Therapeutics Inc
TVTXNASDAQ
Travere Therapeutics (TVTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Travere Therapeutics (TVTX) last issued guidance on January 9, 2023 for fiscal year 2022. The company guided revenue in the range of $212M - $212M for the period.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.28 | $0.23 | $-0.10 | $0.24 |
| Actual | $-0.31 | $-0.10 | $0.05 | $0.37 |
| Surprise | -210.7% | -143.5% | +150.0% | +54.2% |
| Revenue | ||||
| Estimate | $194.7M | $159.3M | $135.3M | $145.6M |
| Actual | $224.6M | $169.6M | $127.2M | $129.7M |
| Surprise | +15.3% | +6.44% | -6.01% | -10.9% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.91 | $0.94 | $0.70 | $0.87 |
| Revenue | ||||
| Consensus | $251.1M | $245.6M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $-0.31 | $0.28 | -210.7 % |
| Q2 | Aug 4, 2026 | $-0.10 | $0.23 | -143.5 % |
| Q1 | May 4, 2026 | $0.05 | $-0.10 | 150.0 % |
| Q4 | Feb 19, 2026 | $0.37 | $0.24 | 54.2 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $224.56M | $194.74M | 15.3 % |
| Q2 | Aug 4, 2026 | $169.58M | $159.32M | 6.44 % |
| Q1 | May 4, 2026 | $127.20M | $135.34M | -6.01 % |
| Q4 | Feb 19, 2026 | $129.69M | $145.59M | -10.9 % |
